| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 … P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ... The Lancet 393 (10167), 143-155, 2019 | 400 | 2019 |
| Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-naïve … P Cahn, J Sierra Madero, J Arribas, A Antinori, R Ortiz, A Clarke, CC Hung, ... JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 21, 156-156, 2018 | 28 | 2018 |
| Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate … J Eron, CC Hung, JG Baril, J Slim, V Falcó, J Bogner, F Maggiolo, A Mills, ... Abstract presented at: HIV DART and Emerging Viruses, 2018 | 4 | 2018 |
| Two-drug regimen of dolutegravir plus lamivudine (DTG+ 3TC) is non-inferior to dolutegravir plus tenofovir/emtricitabine (DTG+ TDF/FTC) at 48 weeks in antiretrovi-ral treatment … C Orkin, N Porteiro, M Berhe, R Dretler, P Viciana, Y Tseng, C Oprea, ... J Int AIDS Soc 21 (Suppl 8), 2018 | 3 | 2018 |
| NÃO INFERIORIDADE DE EFICÁCIA DE DOLUTEGRAVIR (DTG) MAIS LAMIVUDIDINA (3 TC) VERSUS DTG MAIS DOSE FIXA COMBINADA DE TENOFOVIR/EMTRICITABINA (TDF/FTC) EM ADULTOS VIRGENS DE … P Cahn, J Sierra‐Madero, J Arribas, A Antinori, R Ortiz, A Clarke, ... The Brazilian Journal of Infectious Diseases 22, 56-57, 2018 | | 2018 |
